<?xml version="1.0" encoding="UTF-8"?>
<ref id="CR20">
 <label>20.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Xu</surname>
    <given-names>Q</given-names>
   </name>
   <name>
    <surname>Liu</surname>
    <given-names>H</given-names>
   </name>
   <name>
    <surname>Meng</surname>
    <given-names>S</given-names>
   </name>
   <name>
    <surname>Jiang</surname>
    <given-names>T</given-names>
   </name>
   <name>
    <surname>Li</surname>
    <given-names>X</given-names>
   </name>
   <name>
    <surname>Liang</surname>
    <given-names>S</given-names>
   </name>
   <name>
    <surname>Ren</surname>
    <given-names>S</given-names>
   </name>
   <name>
    <surname>Zhou</surname>
    <given-names>C</given-names>
   </name>
  </person-group>
  <article-title>First-line continual EGFR-TKI plus local ablative therapy demonstrated survival benefit in EGFR-mutant NSCLC patients with oligoprogressive disease</article-title>
  <source>J Cancer</source>
  <year>2019</year>
  <volume>10</volume>
  <issue>2</issue>
  <fpage>522</fpage>
  <lpage>529</lpage>
  <pub-id pub-id-type="doi">10.7150/jca.26494</pub-id>
  <?supplied-pmid 30719148?>
  <pub-id pub-id-type="pmid">30719148</pub-id>
 </element-citation>
</ref>
